Perspective Therapeutics (CATX) Stock Forecast & Price Target

→ Historic NVIDIA partnership could send this tiny AI stock soaring... (From Behind the Markets) (Ad)

$11.93

+1.59 (+15.38%)

(As of 06/18/2024 ET)

Perspective Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Consensus Price Target

$19.00
59.26% Upside

High Forecast	$30.00
Average Forecast	$19.00
Low Forecast	$14.00

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Buy	Buy	Buy	N/A
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	6 Buy rating(s)	6 Buy rating(s)	3 Buy rating(s)	N/A
Hold	0 Hold rating(s)	0 Hold rating(s)	0 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$19.00	$19.00	$12.67	N/A
Forecasted Upside	59.26% Upside	64.25% Upside	95.66% Upside	N/A

Get Perspective Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CATX and its competitors with MarketBeat's FREE daily newsletter.

Ad Behind the Markets

Historic NVIDIA partnership could send this tiny AI stock soaring...

After striking partnerships with trillion-dollar chipmaker NVIDIA... ARM surged over 60% in a week... Who's next?

Click here to discover the name and ticker symbol >>>

CATX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CATX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Perspective Therapeutics Stock vs. The Competition

Type	Perspective Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.00	2.70	2.50
Consensus Rating	Buy	Moderate Buy	Hold
Predicted Upside	59.26% Upside	1,068.20% Upside	11.31% Upside
News Sentiment Rating	Positive News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform
6/18/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Overweight
6/14/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform ➝ Outperform	$30.00 ➝ $30.00	+145.90%
5/6/2024	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Dhankher Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/9/2024	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$12.00 ➝ $17.00	+14.48%
11/15/2023	Jonestrading Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$14.00	+503.45%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:03 AM ET.

CATX Forecast - Frequently Asked Questions

What is Perspective Therapeutics's stock forecast and purchase recommendation?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Perspective Therapeutics is $19.00, with a high forecast of $30.00 and a low forecast of $14.00. The consensus rating for Perspective Therapeutics stock is Buy based on the current 6 buy ratings for CATX. Learn more on CATX's analyst rating history.
Do Wall Street analysts like Perspective Therapeutics more than its competitors?: Analysts like Perspective Therapeutics more than other "medical" companies. The consensus rating for Perspective Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CATX compares to other companies.
Does Perspective Therapeutics's stock price have much upside?: According to analysts, Perspective Therapeutics's stock has a predicted upside of 88.81% based on their 12-month stock forecasts.

What analysts cover Perspective Therapeutics?: Perspective Therapeutics has been rated by research analysts at B. Riley, Cantor Fitzgerald, Lifesci Capital, Oppenheimer, and Royal Bank of Canada in the past 90 days.